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ABSTRACT
Acute control of prostaglandin production is
essential for normal estrous cyclicity and maintenance
of early pregnancy.

The rate limiting step for

prostaglandin production is the activation of
Phospholipase A2.

There are many phospholipase A2s,

but few have been investigated in reproductive
studies.

The objective of this study was to examine

PLA2 Groups IV and VI protein and mRNA expression in
the uterine endometrium during the estrous cycle and
early pregnancy in ewes.

Ewes were monitored for

estrous and uterine tissues were collected surgically
on days 5 (n=3), 10(n=3) and 15(n=3) of the estrous
cycle.

Endometrium from pregnant animals were

harvested on days 14(n=3), 15(n=1), 16(n=2), 17(n=1)
or 20(n=2).

Endometrial scrapings were collected in

attempts to harvest luminal epithelial cells primarily
and tissue samples were collected to harvest samples
containing all cellular endometrial components.
Samples were analyzed by western blot analysis and
qRT-PCR to detect protein and mRNA expression of both
PLA2s Group IV and VI.

Western blot results revealed
iv

that protein expression of Group IVA was greatest on
day ten of the estrous cycle but was not significantly
different form days 5 and 15, possibly due to animal
variation.

Group IVA was significantly elevated on

day 14 of pregnancy (P<0.05) and remained elevated
until day 16 when it diminished and a 50kD band
appeared.

Group VIA analysis showed a cross-reactive

50kD band that showed no significant change.

qRT-PCR

analysis for Group IVA of scraping samples revealed
similar findings showing not only an increase of Group
IVA mRNA at pregnancy but also during day 10 of the
estrous cycle (P<0.0001) but little difference was
seen in tissue samples (P<0.0001).

Group VIA was

shown to have no mRNA difference in both tissue and
scraping samples.

These results suggest that PLA2

expression is not the sole regulator of prostaglandin
production, but it does play an integral role that is
tissue and cell type specific in both the estrous
cycle and early pregnancy.
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INTRODUCTION
Estrous Cycle and Early Pregnancy of the Ewe
Maintenance of pregnancy results from complex
communication between the developing embryo and the
maternal unit allowing for the maintenance of the
corpus luteum and resultant progesterone production.
Particular regulatory signals of interest at this time
are prostaglandins.

This thesis will attempt to

provide a basic understanding of the differences in
prostaglandin production between a cyclic animal and
one that is in the early stages of pregnancy.

The

enzymatic cascade that generates prostaglandins will
also be explored for possible points of local
regulation.

Luteolysis and the Regulation of Estrous Cyclicity
Normal estrous cyclicity in ruminants results
from the demise of the corpus luteum (CL), the source
of progesterone (Goff, 2004; Schams and Berisha,
2004), termed functional luteolysis.

Toward the end

of the estrous cycle, prostaglandin F2α (PGF2α), the
luteolytic signal in ruminants, is produced in a
1

pulsatile fashion by the uterine luminal epithelium of
sheep and cattle (McCracken et al., 1972).

Uterine

oxytocin receptor concentrations increase toward the
end of the cycle.

Oxytocin of neurohypophysial and

luteal origin bind oxytocin receptors (OTR) and
initiate pulsatile PGF2α secretion, which in turn,
stimulates release of luteal oxytocin creating a
positive feedback loop that results in a series of
pulses of short duration which are effective in
causing luteolysis.

PGF2α is delivered to the corpus

luteum through a counter-current exchange system
between the utero-ovarian vein and the ovarian artery
(McCracken et al., 1972).

Early in the estrous cycle

oxytocin does not stimulate PGF2α production, but after
progesterone priming (Pate, 1988), oxytocin stimulates
PGF2α production under the influence of estrogen during
an infertile cycle (Barcikowski et al., 1974).
Uterine production of PGF2α in response to oxytocin
coincides with the cyclical variation of OTR
concentration (Roberts et al., 1976). However,
diminished OTR concentration does not fully explain
luteal maintenance during early pregnancy.

For

example, OTR receptor number in pregnant ewes, though
2

decreased, is not limiting (Mann et al., 2001).

Also

lacking clarity is the regulation of the oxytocin
receptor.

It has been documented that the up-

regulation of the estrogen receptor is followed by an
up-regulation of the oxytocin receptor (Spencer et
al., 1996).

Oxytocin regulation by estradiol may be

possible by interaction through the AP-1 and Sp-1
sites on the OTR gene promoter region (Bazer et al.,
2003)since the promoter does not contain an estrogen
response element (Ivell and Walther, 1999).

But,

other studies have documented up-regulation of the OTR
preceding estrogen receptor up-regulation (Wathes and
Hamon, 1993).

In addition neurohypophyseal release of

oxytocin is influenced by gonadal steroids (McCracken
et al., 1996). Cumulatively, these results suggest a
complex regulation of PGF2α production involving
estradiol, progesterone, oxytocin, and their
respective receptors, as well as elements of the
prostaglandin production pathway such as
cyclooxygenases, terminal synthases and
phospholipases, which will later be discussed in
detail.

3

Deviation from Luteolysis During Early Pregnancy
In order to maintain a successful pregnancy, it
is essential that progesterone levels be maintained.
For ruminants to accomplish this, the normal cyclic
progression into luteolysis must be averted (Spencer
et al., 2004; Spencer et al., 2007).

The developing

conceptus signals its presence to the maternal unit
and maintains luteal function.

Upon receiving this

signal, the maternal unit responds by providing an
environment for the growth and development of the
conceptus.
Pulsatile PGF2α production is diminished in
pregnant animals (Peterson et al., 1976) even though
PGF2α production is elevated above basal levels in some
species (Zarco et al., 1988).

Oxytocin stimulation of

PGF2α production in pregnant animals is diminished when
compared to corresponding time periods in cyclic
animals (McCracken, 1980).

OTR concentrations are

reduced in pregnant animals (McCracken, 1980;
Sheldrick and Flint, 1985).

The change in OTR

regulation coincides with the production of a
substance by the embryo between days 12 and 21 in the
sheep that was originally referred to as ovine
4

trophoblast protein-1 (Godkin et al., 1982).

More

recently, this conceptus product was identified as a
unique interferon (Imakawa et al., 1987) and has been
designate interferon-τ (IFNτ )(Roberts et al., 1998).
In all ruminant species investigated, IFNτ has been
implicated as the conceptus product responsible for
the maintenance of early pregnancy.

It has been

proposed that interferon-τ breaks down the positive
feed back loop between oxytocin and uterine PGF2α that
initiates functional luteolysis (Flint et al., 1992).
But, as alluded to earlier, OTR concentrations cannot
completely explain this process (Mann et al., 2001;
Wathes and Hamon, 1993).
Interferon-τ is a protein of 20-24kD produced by
the extra embryonic trophectoderm of ruminants (Farin
et al., 1989; Godkin et al., 1984).

The sheep product

has a mass of 20kD, while the bovine and caprine
isoforms produce higher mass isoforms due to possible
N-glycosylation sites (Baumbach et al., 1990).
Interferon-τ acts by binding high and low affinity
receptors on the endometrium known as IFNAR1 and
IFNAR2 (Godkin et al., 1984; Kaluz et al., 1996).
Interferon-τ binding is thought to initiate an atypical
5

JAK-STAT pathway resulting in the release of several
interferon transcription factors that may directly or
indirectly suppress uterine estrogen receptors (Bazer
et al., 1997; Spencer et al., 2007), cytokines, and a
myriad of enzymes (Hansen et al., 1999; Martal et al.,
1997).

It is speculated that the timing of

interferon-τ expression is genetically programmed
through stimulation and inhibition by transcription
factors associated with blastocyst elongation and
implantation.

It has been demonstrated that the

transcription factors c-fos, c-jun and Ets-2 stimulate
interferon-τ production, in part, by acting at the AP-1
and Ets-2 sites, respectively, that have been
identified in the promoter region of the interferon-τ
gene (Adunyah et al., 1991; Ezashi et al., 1998;
Imakawa et al., 1993; Yamaguchi H, 1999).

The

cessation of interferon-τ expression is not completely
understood but negative regulatory domains have been
identified on the promoter of the bovine interferon-τ
gene (Yamaguchi H, 1999).
The corpus luteum of pregnancy is more resistant
to luteolysis than the corpus luteum of the estrous
cycle.

Studies have shown that pregnant ewes require
6

a higher dose of luteolysins to induce luteolysis when
compared to cyclic ewes (Inskeep et al., 1975;
Nancarrow et al., 1982; Silvia and Niswender, 1986).
One possibility for this action is the increase in PGE2
production (Silvia et al., 1984), a reduction of ECE1
and increased catabolism of PGF2α(Costine et al.,
2007).

PGE2 acts in an opposite manner to that of

PGF2α (Henderson and McNatty, 1975)and may counteract
its effects in the pregnant animal (Magness et al.,
1981).

Prostaglandin Production
Prostaglandins (PG) are key regulators of many
reproductive processes, including those of estrous
cyclicity, pregnancy and parturition (Poyser, 1995).
Concerning ruminant reproduction, the primary focus
has been on PGF2α and PGE2 because these are produced
in greatest concentrations by the endometrial
epithelium during the estrous cycle (Liggins CG et
al., 1980) and pregnancy (Marcus, 1981).
A general overview of the prostaglandin
production pathway, figure 1-1, yields the following
events.

First, membrane phospholipids are cleaved by
7
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Figure 1-1. Schematic of prostaglandin production
phospholipase A2 (PLA2) at the sn-2 position in the
rate-limiting step of PG synthesis resulting in the
release of arachidonic acid (AA) and a resultant
lysophospholipid.

AA is then acted upon by a

cyclooxygenase (COX) in two distinct reactions.
First, the enzyme performs a cyclooxygenase reaction
in which two molecules of O2 are added to AA to form
PGG2.

PGG2 then undergoes a peroxidase reaction where

it is reduced by two electrons to form PGH2.

The

resultant bioactive PGH2 can then be converted into
specific PGs by different PG synthases.

This pathway

has many points of complex regulation and not all are
completely understood.

Better understanding of these

regulatory factors and enzymes may result in the
development of better control of estrous, increased
fertility and novel concepts for contraception.
8

Cyclooxygenases
There are two isoforms of cyclooxygenase, COX-1
and COX-2, which execute the committed step in the
biosynthesis of prostaglandins.

The two enzymes have

similar amino acid sequences (60-65% homology) and
have similar function and activities, with the
predominant structural difference in the membrane
binding domain (Kujubu et al., 1991).

Both

cyclooxygenases are homodimers (Luong et al., 1996)
with each monomer having 3 structural domains:
epidermal growth factor domain, membrane binding
domain, and the catalytic domain.

The epidermal

growth factor domain is found at the N terminus and is
essential for proper folding.

The membrane binding

domain, found adjacent to the epidermal growth factor
domain, is formed by hydrophobic and aromatic residues
that stick out of the helices forming a hydrophobic
patch that can associate with a hydrophobic side of
the membrane bi-layer. The globular catalytic domain
is found at the C terminus and contains a hydrophobic
channel through the center with the upper half
containing the cyclooxygenase active site (Picot et
9

al., 1994).

The globular catalytic domain also

contains many KDEL-like sequences that direct the
cyclooxygenases to the endoplasmic reticulum and the
nuclear envelope, with COX-2 being more readily
associated with the nuclear envelope (Song and Smith,
1996).
There is no real difference in the overall
location of COX1 and COX2 besides the slightly higher
concentration of COX2 around the nuclear envelope and
they operate at similar rates. Each monomer has a
hydrophobic channel that begins at the membrane
binding domain and allows arachidonic acid, which can
diffuse freely within cells, and O2 to enter the enzyme
directly from the lipid bilayer (Luong et al., 1996;
Picot et al., 1994) from which it has been freed by
PLA2s.
Despite the multitude of similarities between the
isoforms, there are discernable differences that,
though not completely understood, allow the two
enzymes to function in different physiological
capacities.

It has been documented that COX -2

releases PGH2 more efficiently than COX-1 at
concentrations of substrate less than 2.5uM
10

(Shitashige et al., 1998; Swinney et al., 1997).
The active site of COX-2 for the cyclooxygenase
reaction is about 20% larger than that of COX-1 caused
in part by a change in the position of helix D at the
membrane binding domain to produce a larger opening
allowing more substrate flexibility for the COX-2
active site (Luong et al., 1996; Picot et al., 1994).
This increased flexibility may aid in substrate
recognition and explain some of the subtle kinetic
differences between the isoforms.
The isoforms are also known to have varying
expressions of mRNA and protein during the estrous
cycle and early pregnancy in many species.

COX-1 is

expressed constitutively in the endometrial epithelium
and stromal cells through out the estrous cycle and
pregnancy in sheep (Charpigny et al., 1997) whereas it
is not expressed at detectable levels in the bovine in
either tissue (Arosh et al., 2002).

This constitutive

expression is not seen with COX-2, which is inducible.
COX-2 mRNA and protein fluctuate greatly during the
estrous cycle and pregnancy in both sheep and cattle.
In cattle, COX-2 mRNA and protein are expressed at a
higher level starting at day 13 and continuing through
11

the estrous cycle (Arosh et al., 2002).

Similarly in

ewes, it appears that COX-2 mRNA and protein are
expressed at basal levels until they are elevated
around days 10-12 and remain elevated until they
decrease between days 14 and 16 of the estrous cycle
(Charpigny et al., 1997; Kim S et al., 2003).
In pregnant ewes COX-2 mRNA expression increases
between days 10 and 12, but remains elevated through
day 16 and declines slowly thereafter (Kim S et al.,
2003).

Despite elevated levels of COX-2 mRNA a

decrease in COX-2 protein has been document past day
17 of pregnancy (Charpigny et al., 1997).

In the

bovine COX-2 protein and mRNA expression remain
elevated to day 24 of pregnancy (Emond et al., 2004).
This time of increased expression coincides with the
production of interferon-τ by the conceptus (Bartol et
al., 1985; Godkin et al., 1982).
COX-2 expression is up-regulated in the
endometrium at the times of luteolysis during the
estrous cycle, pre-implantation, and implantation
during early pregnancy. The fluctuating expression of
the cyclooxygenases at various time points may
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illustrate multiple roles played by eicosanoids during
luteolysis and implantation.
Despite the fact that the cyclooxygenases are the
committed step of prostaglandin synthesis and are
differentially expressed in diverse tissues throughout
the estrous cycle and pregnancy, they do not
independently determine which PGs are synthesized.
They appear to simply be necessary machinery for PG
production but have no bearing on the biosynthetic
fate of their released bioactive PGH2.

Functional Coupling in Prostaglandin Production
The fate of the released PGH2 is decided by the
final action of the terminal synthase that then acts
on the PGH2.

There are several reports of terminal

synthases coupling with both COX-1 and COX-2 (Liou et
al., 2000; Murakami et al., 2000; Nakashima et al.,
2003; Ueno et al., 2001).

Specifically, Murakami et

al. have shown prostaglandin E synthase is coupled
with COX-1 and COX-2 enzymes forming two distinct
pathways in rats.

Each pathway appeared to be

differentially regulated according to AA availability
(Murakami et al., 2000).

Also suggested is that
13

prostaglandin F synthase(PGFS) is coupled with the
COX-2 in HEK293 cells but this observation still needs
clarification concerning the many different types of
PGFS (Nakashima et al., 2003).

As well as terminal

synthases, COX-1 and 2 have been shown to couple with
PLA2s (Ueno et al., 2001).

These findings suggest

compartmentalization of PLA2-COX-Synthase within the
membrane resulting in production of specific
prostaglandins.

Prostaglandin Synthases
PGH2 is subject to conversion into several
different prostaglandins through the action of
specific terminal prostaglandin synthases.

In respect

to luteolysis and recognition of pregnancy, PGE2 and
PGF2α are the most readily produced prostaglandins of
the ruminant uterus and therefore are of the greatest
interest to the current studies (Liggins et al., 1980;
Marcus, 1981).
PGF2α can be produced by several prostaglandin F
synthases and is known to affect physiological
processes in many tissue types, including luteolysis
in ruminants (McCracken et al., 1972).

There are
14

three distinct pathways for PGF2α production. PGD2 11keto reductase has been shown to convert PGD2 to PGF2α
in the presence of NADPH in rabbit liver (Reingold et
al., 1981; Wong, 1981) and rat lung (Watanabe et al.,
1981). PGE2 can also be transformed to PGF2α by PGE2 9keto reductase activity as characterized in the
chicken heart (Lee et al., 1975) and pre-ovulatory
follicles of the ewe (Murdoch and Farris, 1988). The
final common pathway for the formation of PGF2α is
known to be through the action of PGH2 9,11endoperoxide reductase.

This enzymatic activity is

the primary pathway for PGF2α biosynthesis in the
bovine lung (Watanabe et al., 1985), and sheep
vesicular glands (Hamberg and Samuelsson, 1967).

In

addition, other studies have shown PGH2 to be the
primary precursor for PGF2α biosynthesis in the bovine
uterus (Madore et al., 2003).

However, in the bovine

uterus, PGF2α is thought to be produced by a novel PGFS
(Madore et al., 2003) as postulated by Urade and
colleagues (Urade et al., 1995).

Madore et al. showed

that, despite the ability of endometrial cells to
produce PGE2 and PGD2, the primary source of PGF2α comes
15

from the reduction of PGH2.

The reduction most likely

results from the action of the aldoketoreductase 1B5
enzyme (AKR1B5) localized in the luminal and glandular
epithelium. An identifying factor of this enzyme is
the lack of 11-ketoreductase activity that allows most
other PGF synthases to transform PGD2 into PGF2α
(Madore et al., 2003).

In addition to PGFS activity,

AKR1B5 was shown to exhibit 20α-hydroxysteroid
dehydrogenase activity that is involved in the
breakdown of progesterone. This secondary activity may
reduce progesterone’s inhibitory activities that are
seen through diestrous since AKR1B5 is shown to be upregulated by high levels of progesterone (Madore et
al., 2003).

The up-regulation of AKR1B5 in the uterus

begins at day 12 of the cycle and remains elevated
through day 19 approaching luteolysis in cattle
(Madore et al., 2003).

Interestingly, Arosh et al.,

2004 found that AKR1B5 is down regulated in both the
CL and the uterus during the maternal recognition of
pregnancy.

This contradicts reports that PGF2α levels

are elevated from basal levels in some species (Zarco
et al., 1988)suggesting a possible alternate method of
regulation during pregnancy.
16

PGE2, produced by prostaglandin E synthases
(PGES), has many biological activities depending on
the cell type and species. PGE synthases have been
detected in both the microsomal fraction (mPGES)
(Hamberg and Samuelsson, 1973) and the cytosolic
fraction (cPGES) (Ogorochi et al., 1987) of cells.
Microsomal PGES is generally recognized as the
predominant producer of uterine PGE2 and it is found on
the perinuclear membrane co-localized with COX-2
(Murakami et al., 2000).

In the cow uterus overall

mPGES has been documented to be unvarying during the
cycle and during the recognition of pregnancy (Arosh
et al., 2004)despite a documented increase in the
production of PGE2 versus PGF2α (Asselin et al., 1997).
Conversely, PGES mRNA and protein levels increase in
decidual cells and in epithelial cells at the sites of
implantation in rats (Ni et al., 2002).

Combined,

this evidence suggests a specific role for increased
PGE2 production in implantation and decidualization.
Further support of PGE2 as a promoter of pregnancy is
seen in the documented increase of mPGES in the CL
(Arosh et al., 2004)that supports increased PGE2

17

production which may help prevent luteolysis (Pratt et
al., 1977).

Phospholipase A2s
Phospholipase A2s (PLA2) are a broad family of
acylhydrolases that act on the sn-2 position of
membrane phospholipids resulting in the release of AA
and the production of lysophospholipids.

Arachidonic

acid can act as a second messenger (Hallak et al.,
1994)and is a precursor for eicosanoids and several
other chemical mediators.

Also, lysophospholipids can

form an array of important inflammatory mediators in
many different cell types (Graler and Goetzl, 2002).
An example is the metabolization into platelet
activating factor (PAF) (Jackson et al., 1998).
Despite the ability to perform the previously
described reaction, assortments of PLA2s have multiple
enzymatic capabilities.

Due to subtle differences

between enzymes, PLA2s have been divided into 16 groups
with many subgroups to organize over 60 different
enzymes identified as PLA2 isoforms.

These groups

divide the enzymes according to specific substrate
specificity and amino acid sequence and are then
18

further split into sub-groups depending on homology
and splice variants (Six and Dennis, 2000).

This

would seem to be straight forward, but several enzymes
were named before the group designation began,
resulting in several names often describing the same
enzyme.

For simplicity the enzyme will be referred to

by the corresponding group and sub-group designation
in the remainder of the paper.
For the purposes of this study, only a few PLA2
groups were analyzed.

Specifically groups IVA and VIA

are of interest in the present study.

This does not

rule out the activity of other PLA2s in reproductive
physiology, but the aforementioned have been implied
to have function in prostaglandin synthesis and/or are
known to localize in the perinuclear area in close
proximity to the other enzymes involved in
prostaglandin biosynthesis.
As more evidence emerges suggesting functional
coupling of PLA2-COX-Terminal Synthase, PLA2s are
likely candidates to explore as regulators of
prostaglandin production since they catalyze the rate
limiting step in prostaglandin production.

Also, if

specific PLA2s act solely in certain prostaglandin
19

pathways, they can be regulated in target tissues with
minimal impact on other cascades involving AA release.
Elucidation of such pathways will likely yield new
therapeutic options.

PLA2 Group IVA
Group IVA is the best characterized PLA2 of
interest in our current studies.

Its influence has

been shown in multiple tissues with several
physiological functions that all involve the release
of AA and the production of a resultant
lysophospholipid.

The pathway for activation is

controlled by multiple phosphorylation sites that can
be activated by multiple pathways.

It has been

suggested, in some cell types, to be activated
directly through G-protein interaction (Burch et al.,
1986; Jelsema et al., 1987) although more recent
research still suggests a link with the PLC pathway
(Graf et al., 1999; Lee J and Silvia, 1994),or p38
mitogen- activated protein kinase (Waterman et al.,
1996), and extracellular-signal-regulated kinase
(Hazan et al., 1997) in human neutrophils in a PKC
dependant pathway.
20

Group IVA, in its inactive state, is found in the
cytoplasm but has been shown to be translocated to
perinuclear membranes by vimentin fibrils in response
to an influx of Ca++ at concentrations consistent with
those found in physiological responses (Channon and
Leslie, 1990; Nakatani et al., 2000; Schievella et
al., 1995).

Translocation, along with

phosphorylation (Qiu et al., 1993), results in the
active form of the enzyme that is able to process
membrane phospholipids.

Several phosphorylation sites

have been identified, including Ser-437, Ser-454, Ser505, and Ser-727 (de Carvalho et al., 1996), but no
distinct pathway has been divulged for activation (de
Carvalho et al., 1996; Qiu et al., 1993).

Also

demonstrated in fibroblast 3T3 cultures,
phosphorylation of Group IVA must precede the calcium
influx for full activity (Schalkwijk et al., 1996).
It is presently unclear if the timing of
phosphorylation is more imperative for the activity of
the vimentin head or for PLA2 Group IVA activity.

Once

phosphorylated, Nakatani et al., 2000 showed
translocation occurs through the direction of vimentin
21

fibrils attached to the C2 domain of PLA2 Group IVA at
the vimentin head.

Vimentin is believed to assist in

proper localization of Group IVA with specific
membrane associated compartments (Nakatani et al.,
2000).
Group IVA activity in reproductive tissues has
been studied in many species including the mouse,
sheep, human, and bovine.

Gene deletion (knock-out)

studies in mice have associated Group IVA activity
with some prostaglandin regulated functions of
reproduction including implantation and parturition
(Bonventre et al., 1997; Song et al., 2002; Uozumi et
al., 1997).

These Group IVA deficient mice were

characterized as having decreased litter size with
improper implantation and complications with natural
induction of labor (Bonventre et al., 1997; Song et
al., 2002; Uozumi et al., 1997).

Although these

studies clearly illustrate Group IVA’s importance in
regulation of reproductive processes, they do not
delineate Group IVA’s physiological roles during
estrous cyclicity and pregnancy.

Also when compared

with COX-2 knock-out studies, it becomes evident that
other PLA2s are active in AA release allowing for
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reproduction, though at reduced efficiency, whereas
COX-2 deficiency in mice is often fatal and surviving
females are sterile (Langenbach et al., 1999).
Few studies have investigated Group IVAs role in
ruminant reproduction.

Studies in the ewe demonstrate

that Group IVA expression of mRNA and protein during a
simulated estrous cycle remain constant during days
11-14 of the cycle and maintain the ability to respond
to stimulation (Graf et al., 1999).

These data are

further supported in vivo by the demonstration that
samples at multiple time points during the estrous
cycle maintain constant Group IVA activity (Tamby et
al., 1993).

These studies were performed on

endometrial tissue samples that may not contain a high
enough concentration of luminal endometrial
epithelium, the origin of most prostaglandin
production in the uterus(McCracken et al., 1972).
PLA2 activity may be regulated by oxytocin and
interferon-τ since these signals regulate maternal
recognition of pregnancy and luteolysis.

Oxytocin

stimulates PGF2α production which is dependent upon
PLA2 activity; however, oxytocin stimulation of PLA2
does not induce an increase in Group IVA

mRNA,
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protein, or activity in the ewe (Burns et al., 2000;
Graf et al., 1999) suggesting that other PLA2 enzymes
may be involved in maternal recognition of pregnancy
and luteolysis in ruminants(Tithof et al., 2007).
Indirect mechanisms have been suggested in the sheep
(Graf et al., 1999; Lee J and Silvia, 1994) and cattle
(Burns et al., 1997). A proposed mechanism involves
oxytocin induced increases in Ca++ by activation of
phospholipase C pathway resulting in activation of
MAPK/PKC activity leading to full activation of Group
IVA through the Ca++ and phosphorylation activities
described earlier(Burns et al., 1997; Graf et al.,
1999; Lee and Silvia, 1994).

Unlike oxytocin,

interferon-τ appears to directly affect Group IVA
synthesis and activity.

Pregnant sheep exhibited a

steady decrease in Group IVA activity after day 12
(Asselin et al., 1997; Burns et al., 1997; Graf et
al., 1999; Lee and Silvia, 1994).

Similarly,

interferon-τ was shown in bovine endometrial
epithelial cells to decrease Group IVA mRNA and
protein and subsequently decrease PGF2α production
after 12 hours even when stimulated by a phorbol ester
in vitro (Binelli et al., 2000).

Unfortunately,
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interferon-τ’s mechanism for action in either species
is not known and could be through cytosolic and/or
nuclear actions.

Not to be ruled out, as noted by

Bonney et al. 1987, are possible activities of other
PLA2s and species differences in luteolysis and
maternal recognition of pregnancy that have yet to be
classified.

PLA2 Group VI
Group VI PLA2 was first purified in P388D1
macrophage cells although calcium-independent PLA2
activity had been previously described in multiple
species and cell types (Ackermann et al., 1994).
Unfortunately, little is known about the multiple
enzymes and isoforms that are classified within Group
VI.

The gap in knowledge is considerably large with

regards to Group VI’s roles in reproductive processes.
Group VIA is a 85-88kDa protein comprised of 8 Nterminal ankyrin repeats and a conserved lipase motif
(Tang et al., 1997); but, there are multiple splice
variants, see figure 1.2, resulting in many active and
inactive gene products that arise from the same gene
in humans, rats (Forsell et al., 1999; Larsson et al.,
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1998) and most likely some other species. Of these
splice variants, 40kDa and 50kDa variants have been
identified (Ackermann and Dennis, 1995; Brant and
Caruso, 2005; Brant et al., 2006; Manguikian and
Barbour, 2004).

The separate variants have split

Group VIA into 5 different splice variants of known
structure as described by Winstead and colleagues
(Winstead et al., 2000).

Group VIA-1 is an active

phospholipase comprised of 752 amino acids containing

Figure 1-2. Schematic of Group VI Isoforms from
Winstead et al., 2000.
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eight ankyrin repeats and the conserved GTSTG lipase
motif.

Group VIA-2, 806 amino acids, is similar to 1

except, in place of the eighth ankyrin repeat, it
contains a 54 amino acid insertion derived from exon 9
of the human gene which is believed to determine its
localization (Forsell et al., 1999).

Group VIA-3 is

very similar to VIA-2 but at only 640 amino acids it
has a shortened C-terminus and it is not yet known if
this isoform is active.
and Ankyrin-2.

Also produced are Ankyrin-1

These gene products result in inactive

enzymes because they lack the lipase motif despite
containing structure similar to Group VIA-2 and are
dominant negative inhibitors(Forsell et al., 1999;
Larsson et al., 1998; Winstead et al., 2000).
Although the molecular details of Group VI
activity are still largely undefined, the structure
helps to explain some trends that have been identified
in past experiments.

In early studies, Group VI was

found to form a tetramer of 270-350kDa that was
catalytically active (Ackermann et al., 1994; Tang et
al., 1997).

The formation of an oligomeric structure

is most likely due to the protein to protein
interactions common between ankyrin repeats.

It has
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been documented that ankyrin repeats of group VI are
necessary in some capacity for standard activity to be
achieved (Tang et al., 1997).

Structural interaction

between splice variants is also believed to be a point
of regulation for group VI.

Ankyrin-1 and 2 are

believed to bind catalytically competent Group VI PLA2
enzymes, in turn playing an inhibitory role by
preventing the formation of catalytically active
tetramers (Forsell et al., 1999; Manguikian and
Barbour, 2004; Tang et al., 1997).

In some cases

ankyrin repeats also coordinate localization to
phospholipid membranes.

There is mixed evidence for

such sub cellular localization for Group VI.

There

are multiple reports describing both the cytosolic
(Forsell et al., 1999; Saavedra et al., 2006; Tang et
al., 1997) and membrane (Akiba et al., 1999; Forsell
et al., 1999; Manguikian and Barbour, 2004)
localization and activity of these enzymes.

These

results require more experimentation, and suggest that
the localization is not only species, but also cell
type specific.
Several other important regulatory aspects of
Group VI have also been described.

Despite being
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active in the absence of Ca2+ in vitro, Group VI
activity has been shown to be intricately regulated by
calcium stores.

It is known that calmodulin can be

functionally coupled to Group VI in an inhibitory
manner (Wolf and Gross, 1996).

But, this inhibition

can be lifted through localized calcium store
depletion and the actions of calcium/calmodulindependent protein kinase type II in pancreatic islet βcells (Wang et al., 2005).

Also, different kinases

are involved in the activity of Group VI.

PKCα is

imperative to the membrane localization and activity
in P388D1 cells (Akiba et al., 1999; Akiba et al.,
2002)whereas PKCε phosphorylation is implicated in
Group VIA activity in ventricular myocytes (Steer et
al., 2002).

A final kinase implicated is p38 MAPK

which affects Group VI activity in a dose-dependant
manner in smooth muscle cells (Brant and Caruso, 2005;
Yellaturu and Rao, 2003).

Many of these activities

are dependant upon association with ATP (Ackermann et
al., 1994; Steer et al., 2002; Wolf and Gross, 1996).
It has since been shown that ATP acts to protect Group
VI from degradation in oxidation studies (Song et al.,
2006).
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Group VI PLA2 has just as many proposed
physiological roles as points of regulation.

Group VI

has been demonstrated to be a house keeping enzyme
involved in phospholipid remodeling in many cell types
(Baburina and Jackowski, 1999; Barbour et al., 1999;
Herbert and Walker, 2006; Perez et al., 2004; Saavedra
et al., 2006).

But this is not true for all cell

types (Ma et al., 2001; Ramanadham et al., 1999)and is
not the only function for Group VIA.

Group VIA acts

in a signaling fashion promoting the production of
eicosanoids (Akiba et al., 1998; Brant and Caruso,
2005), lysozyme secretion (Balboa et al., 2003), cell
division (Herbert and Walker, 2006; Manguikian and
Barbour, 2004), differentiation (Birbes et al.,
2000)and apoptosis (Balboa et al., 2003; Perez et al.,
2004).

These activities can be stimulated by

exogenous sources (Akiba et al., 1999; Yellaturu and
Rao, 2003) or are initiated by the physiological
intricacies of Group VI splice variant regulation that
varies between cell types and species.

Such variation

makes it difficult to extrapolate results from
previous experiments as universal knowledge.

But, the

previous descriptions provide insight to some
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possibilities for activity and regulation within
reproductive tissues and processes.
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MATERIALS AND METHODS
Materials
All chemicals were purchased from Fisher
Scientific, Pittsburgh, PA unless otherwise noted.
Mature cross-bred ewes were provided by the University
of Tennessee, Knoxville Experiment Station.

Protease

Inhibitor Complete EDTA free tablets were purchased
from Roche Diagnostic Corporation, Indianapolis, IN.
diethylpyrocarbonate (DEPC) was bought from SigmaAldrich, St. Louis, MO.

Correlate EIA kits were

purchased from Assay Designs Inc., Ann Arbor, MI.

BCA

Protein Assay Kit, IgG Anti-rabbit HRP conjugate,
Super Signal West Femto Maximum Sensitivity Substrate,
CL-Xposure X-ray film and PVDF membranes were procured
from Pierce Biotechnology, Rockford, IL.

MagicMark XP

molecular weight markers were purchased from
Initrogen, Carlsbad, CA. High Range Pre-stained SDSPAGE Standards and iScript Select were bought from
Bio-Rad, Hercules, CA.

GIVA specific monoclonal

antibody (SC-454) was obtained from Santa Cruz
Biotechnology, Santa Cruz.

GIV antibody (MAB166A) was

procured from Chemicon International Inc., Temecula,
CA.

IgG Anti-mouse ECL Peroxidase was acquired from
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GE Healthcare Bio-Sciences Corp., Piscataway, NJ.
iPLA2 antibody (Group VIA) was obtained from Upstate
Ltd., Hampshire, United Kingdom.

RNAlater, RLT

buffer, RNeasy Mini Kit, and RNease-Free DNase set
were procured from Qiagen Inc., Valencia, CA.

Power

SYBR was purchased from Applied Biosystems, Foster
City, CA.

All primers were ordered from Integrated

DNA Technologies, Coralville, IA.

Clonetech

Nucleotrap Kit was obtained from Takara Bio Company,
Otsu, Japan.

In Vivo Collection of Luminal Epithelium
Mature cross-bred ewes were monitored for
standing heat twice daily with vasectomized rams.
Upon observation of estrus, sheep were scheduled for
hysterectomy on day 5 (n=3), 10 (n=3), or 15 (n=3) of
the cycle with estrus being day 0 or bred by intact
rams and scheduled for hysterectomy on days 14 (n=3),
15 (n=1), 16 (n=2), 17 (n=1) or 20 (n=2) of pregnancy.
Day of the cycle was further confirmed by macroscopic
evaluation of the reproductive tract (Ireland et al.,
1980; Miyamoto et al., 2000).

Pregnancy was verified

by the presence of an embryo.

Excess blood was
33

removed from the uterus after hysterectomy and it was
placed immediately on ice.

Horns were separated and

opened vertically revealing the luminal epithelium.
Tissue samples were removed containing both epithelium
and stromal layers from each horn with scissors.
Remaining Luminal epithelium was scraped from each
horn with a scalpel.

These samples were weighed and

placed in 3 volumes (w/v) of Western lysis buffer (154
mM NaCl, 1 mM KH2PO4, and 5.6 mM Na2HPO4, 1% NP-40,
0.1% SDS, and 0.5% deoxycholate, pH 7.4 freshly
supplemented with 1mM DTT, and 2.4% (v/v) protease
inhibitor solution composed of 4 Complete EDTA Free
Tablets dissolved in 5mL of water) on ice.

Samples

were immediately homogenized with a Tissumizer SDT1370 (Tekmar, Cincinnati, OH) for thirty seconds on
ice.

Samples were sonicated with a Sonic Dismembrator

100 (Fisher Scientific, Pittsburgh, PA) for 3 pulses
of 10 seconds on ice, aliquoted, and stored at -80oC
until further use.

In Vivo RNA Collection
As the luminal epithelium scrape and tissue
samples were removed from each horn for Western blot
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analysis samples were also obtained, weighed and
placed in 1mL of RNAlater overnight at 40C.

The next

day 1mL of ice cold DEPC treated PBS was added and the
mixture was centrifuged at 5000 x g for 5 minutes at
4oC.

The liquid was then drained and tissue was stored

at -80oC until the RNA could be extracted.

Western Blot
The total protein concentration was determined
using BCA Protein Assay Kit (Pierce Biotechnology,
Rockford, IL) as described by the manufacturers
protocol. Absorbance was measured at 595nM with a
Multiscan RC 96-well plate reader (Lab System
Multiscan RC; Thermo Lab System, Franklin, MA).

10ug

of total protein from each sample was loaded onto a
10% (w/v) SDS polyacrylamide gel and electrophoresed
at 125 V for 1.5 hours. Also added to the gel was one
lane each of chemiluminescent MagicMark XP molecular
weight markers (Initrogen, Carlsbad, CA) and High
Range Pre-stained SDS-PAGE Standards (Bio-Rad,
Hercules, CA) in order to calculate molecular weight,
confirm transfer, and monitor migration during
electrophoresis.

Protein contents were transferred to
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PVDF membranes (Pierce Biotechnology, Rockford, IL)
using the Bio-Rad Transblot SD (Bio-Rad, Hercules, CA)
semi dry transfer system at 1.5 mAmps per cm2 of
membrane for 30 minutes.

Before transfer, the PVDF

membrane and a transfer pad were soaked in 60mM tris
base, 40mM CAPS, and 0.37 M methanol for 30 minutes
while another transfer pad and the gel was soaked in
60mM tris base, 40mM CAPS, and 0.1% SDS.

After

transfer the gels were stained with 0.1% Coomassie
Blue stain to verify transfer.

The membranes were

immediately blocked for 1 hour at room temperature by
shaking in 5% non-fat dry milk (NFDM) in TBST (10 mM
Tris, 0.05% Tween, and 154mM NaCl).

The blocked

membrane was placed in 1mL of primary antibody diluted
with 5% NFDM in TBST to a concentration of 1ug/mL for
Group IVA specific monoclonal antibody, 2ug/mL for
Group IV antibody, and incubated overnight at 4oC.
Group VI antibody was diluted to 1:500.

The

The Group IVA

and IV antibodies recognize different peptides.

This

allows for group IVA to only react with Group IVA and
its various breakdown products where as the Group IV
antibody can also recognize other Group IV PLA2s such
as Group IVC. After incubation, membranes were washed
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4 times in 200mL of TBST for 5 minutes.

1mL

corresponding secondary antibody diluted by 5% NFDM in
TBST was applied at a dilution of 1:5000 for IgG Antimouse ECL Peroxidase or 1:1000 for IgG Anti-rabbit HRP
conjugate (Pierce Biotechnology, Rockford, IL)
incubated for 2 hours at room temperature.

and

Membranes

were then washed in 200mL of TBST 3 times for 20
minutes each.

Super Signal West Femto Maximum

Sensitivity Substrate was used according to
manufacturer’s instructions. Protein bands were
visualized by a 30 second exposure to CL-Xposure X-Ray
film.

Band intensity was analyzed with the FluoroChem

5500 (Alpha Innotech, San Leandro, CA) for
densitometry values.
Both Group IV antibodies are mouse monoclonal
antibodies and recognize a sequence in the first 216
amino acids.

Exactly which sequences are recognized

is not disclosed by either manufacturer.

The primary

antibody from santa cruz biochemical claims to be
specific to Group IVA.

Chemicon’s Group IV antibody

recognizes Group IVA and other Group IV isoforms.
Both antibodies will recognize group IVA and may also
cross react with breakdown products or novel PLA2s yet
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to be classified.

Similarly the Group VIA antibody

recognizes a peptide that to date is specific to Group
VIA.

The antibody will recognize Group VIA and some

cleavage products but an uncharacterized PLA2 is not
outside of the realm of possibilities.

RNA Extraction
Tissue and scraping samples treated with RNAlater
were thawed, weighed and homogenized for two 20 second
bursts with a Tissumizer SDT-1370 in 600 uL of RLT
buffer per 20mg of sample.

Samples were then

centrifuged at 10,000 x g for 5 minutes and the
supernatant collected for RNA extraction.

RNeasy Mini

Kit spin columns were used for extraction and DNA
contamination was removed with an on column RNeaseFree DNase Kit treatment.

200uL of supernatant was

added to each spin column and manufacturer’s
instructions were followed with the addition of a 5
minute incubation after the addition of RPE buffer.
RNA was eluted in 50uL of RNase free water.

RNA

integrity was evaluated using an Agilent 2100
Bioanalyzer (Agilent Life Sciences and Chemical
Analysis, Foster City, CA).

Final RNA concentration
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was determined using a ND-1000 Spectrophotometer
(Nanodrop Technologies, Wilmington, DE) and samples
were stored at -80oC.

Reverse Transcription
Reverse transcription of RNA samples was
performed using iScript Select following the
manufacturer’s instructions using the supplied oligo
d(T) primer.

500ng and 175ng of total RNA were added

to each reaction for scrape and tissue samples,
respectively.

After reverse transcription the cDNA

samples were stored at -20oC until use in real time
PCR.

Semi-quantitative Realtime PCR (qRT-PCR)
cDNA was diluted with DEPC water to 1:5, 1:25,
and 1:125 for each sample.

2uL of each dilution was

plated in duplicate wells along with forward and
reverse primers (500nM) and 12.5uL of Power SYBR and
DEPC water resulting in a 25uL reaction volume.

Also,

a control sample of the previous dilutions was plated
for quantitative analysis (sheep 121).

Analysis was

performed under universal conditions with an ABI 7000
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Sequence Detection System (Applied Biosystems, Foster
City, CA).

Ribosomal protein L19 was used as a

reference gene with primer sequences of
ACCCCAATGAGACCAATGAAAT (F) and CAGCCCATCTTTGATCAGCTT
(R) (Chen et al., 2006).

Phospholipase Group IVA was

analyzed using the following primer sequences
GGAAACCATAAAGGAGAACATGAAGAA (F) and
GCACATCACGTGTAGAATGCAA (R).

These were designed using

Primer Express software (Applied Biosystems, Foster
City, CA) to choose primer pairs that span across
exons of the bovine sequence (NM_001075864) described
by ensemble.

Partial sheep sequences, produced by our

lab, were examined with Primer Express software for
phospholipase Group VIA primer generation. Comparison
with the bovine sequence for GVIA variant-2
(XM_615452.3) was used to determine possible splice
sites. Phospholipase Group VIA was evaluated using as
CGCACGTGGGACTGCAT (F) and GGTGGCAACTGGGAACAATACT (R)
as primer sequences.

Clontech Nucleotrap Kit (Takara

Bio Company, Otsu, Japan) was used to purify PCR
products for subsequent sequencing at University of
Tennessee, Knoxville Molecular Biology Resources
Facility in order to validate primer specificity.

A
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melting curve was also generated following PCR
analysis in order to detect any primer dimmers or
false products in the reactions.

Statistical Analysis
All statistical analysis was performed using SAS
9.1 software (SAS Institute, Cary, NC).

Densitometry

values obtained from Western blot data were analyzed
with the following model, y = μ + treatment +
sheep(treatment) + ε, with each antibody being analyzed
separately.

Pairwise contrasts were performed between

each treatment to determine differences.

Analysis of

qRT-PCR data for primer efficiency was performed, as
described by Yuan et al., using a simple linear
regression, Ct= βo+ βconXlcon+ε, to determine data quality
and primer efficiency (Yuan et al., 2006).

PROC GLM

was used to construct a multiple regression model,
Ct=βo+βconXicon+βgeneXigene+βtreatXitreat+βcontreatXiconXitreat+βcongene
XiconXigene+βgenetreatXigeneXitreat+βcongenetreatXiconXitreatXigene+ε also
described by Yuan et al., in order to estimate ΔΔCt
number which was the ΔCt for RPL19 minus ΔCt for the
target gene between our target and control samples
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(Yuan et al., 2006).

A general linear model, y = μ +

treatment + sheep(treatment) + ε, was used to analyze
differences of the means between the ΔΔCt numbers of
each treatment.

qRT-PCR data are presented as fold

change (2-ΔΔCt)and significance for all experiments was
determined as P < 0.05.
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RESULTS
Western blot analysis during the estrous cycle
Western blot analysis of proteins prepared from
luminal endometrial epithelial scrapings collected
from animals over the estrous cycle revealed (Figure
3-1) a protein that migrated to a position coinciding
with 108kD.

This protein was visualized with both

group IV and Group IVA specific antibodies leading to
the conclusion that this protein is PLA2 Group IVA.
Statistical analysis of densitometry values (Figure 32) revealed that the greatest Group IVA expression
during the estrous cycle occurred at day 10 of the
cycle before becoming diminished again at day 15.
However, days 5, 10, and 15 were not seen to be
statistically different.

Also seen were 45 and 50kD

bands that do not correspond to any previously
reported group IV or IVA cross reactive proteins.

1

2

3

4

5

6

108kD
Figure 3-1. Representative expression of PLA2 Group IVA
during the estrous cycle. Lanes 1&2 Day 5 (n=3).
Lanes 3&4 Day 10 (n=3). Lanes 5&6 Day 15 (n=3).
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Figure 3-2. Estimated densitometry values for PLA2
Group IVA blot (Day 5=6831.33, Day 10=9289.67, and Day
15=7041.33).
Western blot analysis of pregnant ewes
Western blot analysis of proteins prepared from
luminal endometrial epithelial scrapings of pregnant
sheep between days 14 and 20 of pregnancy also revealed
(Figure 3-3) a protein that migrated to a position of
108kD.

This protein was identified as Group IVA by using

both a group IV non-specific and a Group IVA specific
antibody as described previously.

Protein expression, as

determined by densitometry (Figure 3-5), was shown to be
highest at days 14 and 15 of pregnancy.

Pair wise

comparison revealed that Group IVA expression decreased
following day 15 of pregnancy (P<0.04).
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Also of interest is the appearance of cross
reactive proteins against both the Group IV and Group
IVA antibodies between days 15 and 17 (Figure 3-4) of
pregnancy that migrates to positions of 68kD and 38kD.
No Group IV cross reactive proteins have been
documented at this position.

The 68kD protein

exhibits greatest expression on day 16 of pregnancy
where as the 32kD protein remains relatively
consistent from day 14 to 17.

There are also 45kD and

50kD proteins that are cross reactive with the group
IV and Group IVA antibodies that reveal no defined
pattern and at this time can only be considered as
possible breakdown products until further study.
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108kD
Figure 3-3. Expression of PLA2 Group IVA during
pregnancy. Lanes 1&2: Day 14 of pregnancy. Lane 3:
Day 15 of pregnancy. Lane 4&5: Day 16 of pregnancy.
Lane 6: Day 17 of pregnancy. Lanes 7&8: Day 20 of
pregnancy
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Figure 3-4. Expression of PLA2 Group IV during
pregnancy. Lanes 1&2: Day 14 of pregnancy. Lane 3:
Day 15 of pregnancy. Lane 4&5: Day 16 of pregnancy.
Lane 6: Day 17 of pregnancy. Lanes 7&8: Day 20 of
pregnancy.
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Figure 3-5. Estimated densitometry values for PLA2
Group IV blot (Day 14P=9589.5, Day 15P=7065.00, Day
16P=3987.5, Day 17P=2917, and Day 20P=1906.5).
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Western blot analysis of pregnancy versus nonpregnancy
Western blot analysis of pregnant and non-pregnant
samples with both Group IV and Group IVA antibodies
reveals similar results as seen in the pregnancy and
estrous cycle blots described earlier.

But, from this

blot it is determined that group IVA (Figure 3-6) is
expressed at its highest level on days 14 and 15 of
pregnancy before decreasing as described previously.

Day

14 of pregnancy was shown to be significantly higher than
day 15 of the estrous cycle (P<0. 05). This blot once
again demonstrated not only the band corresponding to
Group IVA, but also the unidentified 68, 32, 50 and 45kD
bands that were described earlier.
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Figure 3-6. Expression of PLA2 Group IV. Lanes 1&2: Day
5. Lanes 3&4: Day 10. Lanes 5&6: Day 15. Lanes 7&8:
Day 14 of pregnancy. Lane 9: Day 15 of pregnancy. Lane
10&11: Day 16 of pregnancy. Lane 12: Day 17 of
pregnancy. Lane 13: Day 20 of pregnancy.
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qRT-PCR Analysis of endometrial epithelium
All samples were analyzed by qRT-PCR in order to
demonstrate the fluctuations of phospholipase A2 mRNA
during the estrous cycle and early pregnancy.
Analysis of Group IVA expression by luminal
endometrial epithelial scrapings (Figure 3-7) revealed
greatly elevated expression (P<0.0001) at day 10 of
the estrous cycle (11.59), followed by day 14 of
pregnancy (2.197).

That level was reduced during days

5 and 15 of the estrous cycle (0.744,0.613) and
15 and 16 of pregnancy (0.613,1.013).
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Expression
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(n=1) (n=2)

Figure 3-7. Analysis of qRT-PCR results for Group IVA
scrape mRNA expression reported as 2-ΔΔCt. Error bars
represent the 95% confidence intervals with letter
grouping representing significance.
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was greatly decreased after day 16 of pregnancy with
the lowest expression occurring at day 17 of pregnancy
(0.051).
Group IVA mRNA expression in tissue samples
(Figure 3-8) did not show differences between most
treatments (P<0.001).

Similar to the results seen

from endometrial scrapings, the tissue samples showed
days 5 and 15 of the estrous cycle (0.273,0.339) once
again had decreased expression with day 10 exhibiting
a significant increase.

Unlike the scraping samples,

all pregnant samples expressed Group IVA mRNA at
increased levels that were comparable to expression on
day 10 of the estrous cycle with day 14 of pregnancy
(1.917) exhibiting the highest expression.
Group VIA expression in scraping samples (Figure
3-9) revealed elevated mRNA expression at days 5 and
10 of the estrous cycle (0.487,0.792) and decreased
expression on day 15 of the estrous cycle(P<0.0002).
The highest mRNA expression levels were observed on
day 10 and the lowest were observed on day 15 of the
estrous cycle (0.115).

Expression from all pregnant

time points for Group VIA was diminished and did not
significantly differ from one another.
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Tissue samples (Figure 3-10) showed virtually no
significant difference in Group VIA expression
(P<0.0062).

Day 15 of the estrous cycle (0.656) and

days 14 and 20 of pregnancy (0.673,1.232) were seen to
be the highest in Group VIA mRNA expression with the
remaining being slightly decreased.

The day 20 value

may be an artifact due to decreased replications of
this treatment.

Day 20 tissue RNA extraction only

yielded one viable sample.
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Figure 3-8. Analysis of qRT-PCR results for Group IVA
tissue mRNA expression reported as 2-ΔΔCt. Error bars
represent the 95% confidence intervals with letter
grouping representing significance.
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Figure 3-9. Analysis of qRT-PCR results for Group VIA
scrape mRNA expression reported as 2-ΔΔCt. Error bars
represent the 95% confidence intervals with letter
grouping representing significance.
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Figure 3-10. Analysis of qRT-PCR results for Group VIA
tissue mRNA expression reported as 2-ΔΔCt. Error bars
represent the 95% confidence intervals with letter
grouping representing significance.
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DISCUSSION
Mouse knock-out studies have identified both
cyclooxygenases and PLA2 Group IVA enzymes to be
essential to many reproductive processes.

Langenbach

and colleagues demonstrated that COX-1 knockouts
developed normally and were relatively healthy.
Reproduction appeared to be normal in both male and
female COX-1 deficient mice with normal litter size
and development. Only the initiation of labor in
homozygous COX-1 matings appeared to be problematic in
some animals (Langenbach et al., 1995).

Later

studies found that labor could be initiated by
administering PGF2α suggesting a COX-1 specific pathway
for PGF2α production at the time of parturition
(Sugimoto et al., 1997).

COX-2 deficient mice

exhibited marked differences when compared with normal
mice or COX-1 deficient mice.

COX-2 deficient mice

showed decreased survivability with only 60% of pups
surviving to weaning and only 75% of those survived a
year (Morham et al., 1995).

The surviving females

were infertile (Morham et al., 1995).

Lim and

associates took an in depth look at the causes of
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infertility in COX-2 deficient mice.

The most likely

cause of infertility was due to failed ovulation and
severely hampered oocyte development.

Outside of

unsuccessful ovulation and oocyte maturation, the
transfer of normal blasocysts into COX-2 deficient
dams revealed severely restricted implantation and an
inhibited decidualization reaction (Lim et al., 1997).
Bonventre and associates demonstrated that PLA2 Group
IVA knockouts have similarities with both COX-1&2
knockouts.

Like COX-1, Group IVA deficient mice were

seen to develop normally with a typical lifespan.
Unlike COX-1 knockouts, Group IVA deficient mice had
decreased reproductive efficiency with decreased
litter size and improper spacing of implantation sites
(Bonventre et al., 1997; Song et al., 2002).

The

pups at parturition, though anatomically normal, were
born dead due to problems with the initiation of labor
(Bonventre et al., 1997) similar to results seen in
COX-1 studies.

Such results implicate Group IVA’s

involvement in reproduction though it is not clear
what roles it plays in the processes of
decidualization, implantation, and parturition.

When

both cyclooxygenase and Group IVA knockout results are
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compared it is of interest that the COX-2 knockout
resulted in sterility on many levels where as Group
IVA knockout significantly reduced fertility but did
not completely inhibit the reproductive process.

Such

results implicate that, though efficiency may be
reduced, alternate PLA2s may be responsible for, or act
in redundancy with PLA2 GIVA in initiating AA release
allowing for reproductive processes to continue.
Group IVA protein expression in endometrium
samples was demonstrated to be consistent across the
estrous cycle with similar levels of activity at
different time points (Graf et al., 1999).

These

findings are consistent with statistical results from
western blot analysis (Figures 3-1 and 3-2) which
showed no difference in protein expression between
endometrial epithelium samples from day 5, day 10 and
day 15 of the estrous cycle despite being numerically
increased at day 10 of the cycle.

Group IVA mRNA

expression in endometrium samples (Figure 3-8),
containing stroma, glands, and blood vessels, was seen
to have only a slight increase at day 10 of the
estrous cycle of approximately 25% which is similar to
previously seen results in endometrial samples (Graf
54

et al., 1999).

This is puzzling due to the change in

prostaglandin production during this time.
Specifically, PGF2α production increases as the estrous
cycle progresses.

PLA2, the rate limiting enzyme in

prostaglandin production, would be expected to alter
its expression and/or activity.

Conversely, Group IVA

protein expression in endometrium samples appeared to
remain relatively constant and shows no response to
oxytocin stimulation despite the ability of broad
spectrum PLA2 inhibitors to block PGF2α production (Lee
and Silvia, 1994).

Such results suggest an

alternative regulation of the prostaglandin production
pathway that may act through different tissues, a down
stream enzyme in the cascade, another PLA2 whose
activity is yet to be characterized, or regulation of
enzyme activation.
Interestingly, a distinct increase, by 16 fold,
of Group IVA mRNA was seen in luminal epithelial
scraping samples at day 10 of the cycle (Figure 3-7).
This level then returned to a level similar to that
seen on day 5 of the cycle by day 15.

These results

contradicted those previously seen (Graf et al., 1999)
in endometrial samples.

This discrepancy between
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sample types seen both in COX-2 (Charpigny et al.,
1997; Kim et al., 2003)and Group IVA expression
identifies the key role that the epithelial cell layer
plays in prostaglandin production and uterine
regulation.

Western blot analysis of endometrial

epithelium also showed an increase at day 10 of the
estrous cycle (Figures 3-1, 3-2, & 3-6).
Unfortunately the increase is not significant when
densitometry values were analyzed.

With the

development of internal controls, such as β-actin,
allowing for normalization, gel to gel comparison and
increased number of samples, the increased protein
expression at day 10 of the cycle may become
significant due to greater statistical power.

The

development of internal controls would be necessary
since there are no pure forms for each of our target
proteins currently available for standard curve
generation in order to normalize the data obtained
from densitometry analysis.

These results are

supported by the qRT-PCR findings in endometrial
epithelium (Figure 3-7).

Also, the naked eye detects

a difference especially when viewing the western blot
of our most representative samples (Figure 3-6).
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These results follow more closely the physiological
production of prostaglandin and reported production of
prostaglandins specifically by the luminal endometrial
epithelium (McCracken et al., 1972).

Though the

insight into Group IVA protein and mRNA expression is
valuable it does not completely explain the regulation
of prostaglandin production since there are multiple
regulatory events controlling maximal activity, such
as calcium influx and phosphorylation, yet to be
characterized in this model.
PLA2 expression during early pregnancy exhibits
dramatic changes (Figures 3-3, 3-4 & 3-5).

At day 14

of pregnancy, the time of early interferon-τ production
by the trophoblast in sheep, group IVA protein was
seen to be elevated when compared with day 15 of the
estrous cycle (Figure 3-6). Group IVA mRNA was also
increased 3 fold in luminal epithelial scrapings at
this time (Figure 3-7).

Conversely, interferon-τ was

shown in vitro to suppress group IVA expression and
decrease PGF2α production in BEND cells stimulated by
phorbol esters.

Our results support in vivo

prostaglandin production which increases during early
pregnancy in sheep (Silvia et al., 1984). In addition,
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the promoter region of the Group IVA gene contains
multiple interferon response elements (Wu et al.,
1994) which could result in its up regulation in vivo.
Tamby and colleagues observed that PLA2 activity
decreased beginning at day 12 of pregnancy in the ewe
(Tamby et al., 1993).

Our results do not show a

significant decrease in Group IVA protein or mRNA
expression until day 16 of pregnancy in luminal
epithelial scrapings (Figures 3-3 & 3-7).

The

discrepancy between the day of decrease in expression
and activity is due to animal, sample, or methodology
differences.

Endometrium samples were observed to

have no variation in Group IVA mRNA expression (Figure
3-8) between day 15 of the estrous cycle and all days
of pregnancy tested.

Also, an intact enzyme does not

denote activity due to the involvement of further
processing and cofactors resulting in maximal activity
as discussed earlier.

Interestingly, the decrease in

Group IVA protein and mRNA expression on day 16 of
pregnancy in our study coincides with maximal
interferon-τ production by the embryo (Bartol et al.,
1985; Godkin et al., 1982).

Further study is needed
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to determine if interferon-τ directly or indirectly
stimulates these changes.
Interestingly, there was an appearance of 68 and
32kD Group IVA cross reactive proteins during days 1517 of pregnancy with maximum expression on day 16 of
pregnancy (Figures 3-4 & 3-6).

The proteins were

recognized by both the Group IV and Group IVA specific
antibodies.

These findings have not been reported in

in vivo samples before, but similar findings have been
demonstrated in studies of Group IVA cleavage by
caspases(Adam-Klages et al., 1998; Luschen et al.,
1998).

Early reports demonstrated that caspase-3, 4,

and 8 possessed the ability to cleave PLA2 group IVA to
enzymatically inactive 68/70kD and 32kD fragments
(Adam-Klages et al., 1998; Luschen et al., 1998).
Later studies found the 68/70kD fragment had greater
membrane affinity than the intact enzyme resulting in
dual competitive inhibition for membrane/substrate
binding and phosphorylation (Atsumi et al., 2000).
Caspase activity has been shown to be increased in the
presence of interferon-α (Boccellino et al., 2004).
Collectively this may suggest an interferon mediated
mechanistic shift away from inflammation, similar to
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that noted during apoptosis, allowing differentiation
and successful implantation without initiation of an
inflammatory response.

Another point of interest is

the timing of possible caspase cleavage of Group IVA.
This appears to occur at or after day 16 of pregnancy.
At this time the uterus is preparing for implantation
and decidualization in sheep (Spencer et al., 2004).
This is a time of cellular reorganization in which
caspases have been implied in other tissues to play an
essential role in the cascade signaling for terminal
differentiation (Okuyama et al., 2004) resulting in
the restructuring of cellular membranes and function.
A final result of interest is the lack of change
in Group VIA mRNA with in both endometrium and
endometrial epithelial samples (Figures 3-9 & 3-10).
Previous studies had shown a sharp decrease in PGF2α
production when Group VIA was inhibited by bromoenol
lactone in endometrial cell cultures under the
stimulation of oxytocin (Tithof et al., 2007).

Such

results implicate changes in Group VIA expression
and/or activity as a key factor in PGF2α production at
the time of luteolysis.

Our mRNA and western blot

results did not support such findings in vivo.
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Western Blots (not pictured) were seen to be
inconclusive yielding a faint unidentified 50kD band
that was constitutively expressed.

A similar band was

recognized as a caspase-3 cleavage product by Lauber
and associates but it’s activity was never described
(Lauber et al., 2003). Such results may be due to the
lack of sheep specific antibodies.

The qRT-PCR

results displayed minimal expression of Group VIA when
compared with Group IVA, with little change between
day of the cycle or early pregnancy in both
endometrial and endometrial epithelium samples.
A preliminary result sparking curiosity was that
a previous preparation of samples abandoned by our lab
involving multiple high speed centrifugations after
sonication, yielded a 28kD band that appeared to
increased during the estrous cycle and become
diminished in early pregnancy.

Though further

research is needed for verification, this could be the
result of Group VIA cleavage by caspase.

Group VIA

can be cleaved by caspase-3 resulting in a 28kD
fragment that increases fatty acid release in
apoptotic cells (Atsumi et al., 2000; Lauber et al.,
2003).

If this were the case, the rapidly changing
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endometrial cells may undergo a change resulting in an
increase in localized caspase-3 activity that would
splice the small amounts of Group VIA into active 28kD
enzymes resulting in increased activity.

Zhoa and

colleagues have identified a unique pathway in ovarian
cancer cells that does not induce apoptosis in which
Caspase-3 cleaved Group VIA produces lysophosphatidic
acid which in turn initiates the activation of Group
IVA causing an increase in AA production (Zhao et al.,
2006).

Increased release of AA by cleaved Group VIA

and activated Group IVA may result in elevated
prostaglandin production that is seen in response to
oxytocin.

Further investigation of protein expression

and activity is needed using PLA2 activity assays and
western blot analysis to verify this theory.
These findings further implicate the role of PLA2s
in complex regulations that maintain proper uterine
function during the estrous cycle and early pregnancy.
Though PLA2’s expression is not the sole regulator of
prostaglandin production, PLA2s do play an integral
role that is tissue and cell type specific.

Their

roles appear to be intertwined with the processes of
the estrous cycle and early pregnancy both as
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substrates and enzymes within multiple cascades that
allow for their activity in divergent processes.
Future studies should explore the expression of other
PLA2s, such as secretory PLA2s, in these tissues as
well as the activity of all studied isoforms to
further elucidate the relevance of the previous
findings.
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